Akèy › Lukemi lenfositè kwonik › Iowa › Cedar Rapids
Etid klinik pou Lukemi lenfositè kwonik nan Cedar Rapids, IA
7 etid pou Lukemi lenfositè kwonik ap chèche patisipan nan sit nan ak bò kote Cedar Rapids (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Ap rekriteFaz 3
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Ap rekriteFaz 3
- Physicians' Clinic of Iowa PC, Cedar Rapids
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Ap rekriteFaz 3
- University of Iowa Hospitals and Clinics, Iowa City · 25 mi lwen
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Ap rekriteFaz 1/2
- University of Iowa Hospitals and Clinics, Iowa City · 25 mi lwen
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Ap rekriteFaz 3
- University of Iowa Health Care. ( Site 0017), Iowa City · 25 mi lwen
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Ap rekriteFaz 2
- University of Iowa, Iowa City · 25 mi lwen
Etid Lukemi lenfositè kwonik nan lòt vil
- Boston, MA31 etid
- Columbus, OH28 etid
- Durham, NC27 etid
- Washington, DC22 etid
- Seattle, WA20 etid
- Rochester, MN19 etid
- New York City, NY18 etid
- Houston, TX17 etid
- Baldwin Park, CA16 etid
- Milwaukee, WI15 etid
- Cincinnati, OH14 etid
- Chicago, IL14 etid
Lòt etid nan Cedar Rapids
- Kansè Poumon ki pa ti selil20 etid
- Kansè nan tete17 etid
- Leksemi mieloïd egi16 etid
- Kansè (tout kalite)15 etid
- Myelom Miltip15 etid
- Kansè poumon14 etid
- Kansè kolorektal13 etid
- Kansè pwostat12 etid
- Karsinòm selil skuamèz tèt ak kou12 etid
- Melanom10 etid
- Akidan serebavaskilè10 etid
- Kansè Metastatik9 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.